ceralasertib

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

A blood test for tuberculosis that can distinguish between dormant and active infections has shown promise in a clinical trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.